ES3072067T3 - Crystalline forms - Google Patents

Crystalline forms

Info

Publication number
ES3072067T3
ES3072067T3 ES22849645T ES22849645T ES3072067T3 ES 3072067 T3 ES3072067 T3 ES 3072067T3 ES 22849645 T ES22849645 T ES 22849645T ES 22849645 T ES22849645 T ES 22849645T ES 3072067 T3 ES3072067 T3 ES 3072067T3
Authority
ES
Spain
Prior art keywords
piperidin
oxo
oxoindolin
dimethyl
phenylbutan
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES22849645T
Other languages
English (en)
Spanish (es)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Raqualia Pharma Inc
Original Assignee
Raqualia Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Raqualia Pharma Inc filed Critical Raqualia Pharma Inc
Application granted granted Critical
Publication of ES3072067T3 publication Critical patent/ES3072067T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
ES22849645T 2021-07-30 2022-08-01 Crystalline forms Active ES3072067T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163227692P 2021-07-30 2021-07-30
PCT/JP2022/029430 WO2023008585A1 (en) 2021-07-30 2022-08-01 Crystalline forms

Publications (1)

Publication Number Publication Date
ES3072067T3 true ES3072067T3 (en) 2026-06-29

Family

ID=85087024

Family Applications (1)

Application Number Title Priority Date Filing Date
ES22849645T Active ES3072067T3 (en) 2021-07-30 2022-08-01 Crystalline forms

Country Status (11)

Country Link
US (2) US12552776B2 (de)
EP (1) EP4377309B1 (de)
JP (1) JP7765130B2 (de)
KR (1) KR20240042400A (de)
CN (1) CN117616022A (de)
BR (1) BR112023025271A2 (de)
CA (1) CA3223173A1 (de)
ES (1) ES3072067T3 (de)
MX (1) MX2024000903A (de)
TW (1) TW202321216A (de)
WO (1) WO2023008585A1 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12605394B2 (en) 2024-07-25 2026-04-21 Visionary Assets, Llc Compositions containing cannabinoid nanoparticles
US12667578B2 (en) 2024-07-25 2026-06-30 Visionary Assets, Llc Cryogenic process for making cannabinoid nanoparticles and compositions made thereby

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006221699A1 (en) 2005-03-11 2006-09-14 Pfizer Inc. Crystal forms of an imidazole derivative
JP5663743B2 (ja) 2009-02-27 2015-02-04 ラクオリア創薬株式会社 モチリン受容体作動活性を有するオキシインドール誘導体
CN103702995B (zh) 2011-05-18 2016-04-13 拉夸里亚创药株式会社 4-{[4-({[4-(2,2,2-三氟乙氧基)-1,2-苯并异噁唑-3-基]氧}甲基)哌啶-1-基]甲基}-四氢-2h-吡喃-4-羧酸的多晶型形式
UY34094A (es) 2011-05-27 2013-01-03 Novartis Ag Derivados de la piperidina 3-espirocíclica como agonistas de receptores de la ghrelina
WO2013164790A1 (en) 2012-05-03 2013-11-07 Novartis Ag L-malate salt of 2, 7 - diaza - spiro [4.5 ] dec- 7 - yle derivatives and crystalline forms thereof as ghrelin receptor agonists
JP6572414B2 (ja) 2014-05-20 2019-09-11 ラクオリア創薬株式会社 ベンズイソオキサゾール誘導体塩

Also Published As

Publication number Publication date
CN117616022A (zh) 2024-02-27
BR112023025271A2 (pt) 2024-02-27
JP2024526952A (ja) 2024-07-19
EP4377309A4 (de) 2025-06-25
US20260146036A1 (en) 2026-05-28
EP4377309C0 (de) 2026-05-20
TW202321216A (zh) 2023-06-01
CA3223173A1 (en) 2023-02-02
US12552776B2 (en) 2026-02-17
US20240351998A1 (en) 2024-10-24
EP4377309B1 (de) 2026-05-20
WO2023008585A1 (en) 2023-02-02
KR20240042400A (ko) 2024-04-02
JP7765130B2 (ja) 2025-11-06
EP4377309A1 (de) 2024-06-05
MX2024000903A (es) 2024-02-06